Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of Needle-Free Vaccines and to Help Eradicate Measles

Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, today announced a $23.6 million grant from the Bill & Melinda Gates Foundation that will fund mass production of needle-free vaccines.  The manufacturing facility will enable commercialization of the first microarray technology-based measles-rubella vaccine, indicated for children as young as 9 months, once approved by the appropriate regulatory authorities following additional clinical study.

In low- and middle-income countries, measles remains a leading cause of death, primarily due to limited access to vaccines that require refrigeration during transport and storage and clinicians to administer them.  Micron is developing a needle-free version of the measles-rubella (MR) vaccine based on its microarray technology.  The technology reduces the need for a cold chain and allows a community health worker to vaccinate a child within minutes by applying the technology to the skin and pressing a button that confirms administration. The administration of the vaccine is virtually pain-free.

“Vaccines are among the most effective and cost-effective tools to prevent measles and rubella, diseases that account for an estimated 350 deaths per day with a disproportionate impact on people living in low- and middle-income countries1,” said James Goodson, Senior Scientist and Epidemiologist in the Global Immunization Division at the Centers for Disease Control and Prevention (CDC). “Microarray-based measles-rubella vaccines could provide an alternative approach to delivering these life-saving vaccines to children in regions with some of the highest rates of unimmunized children in the world and could help overcome some of the most substantial barriers to eradicating measles and rubella globally.”

According to the World Health Organization, all children should be vaccinated against measles between the ages of 9 and 15 months, then again between 15–18 months2. Earlier this year, Micron announced successful clinical data from a phase I/II study in the Gambia, which evaluated the safety, immunogenicity, and acceptability of the leading commercially available MR vaccine delivered by Micron’s microarray technology in adults, toddlers and infants as young as 9 months old.

“We’re grateful to the Bill & Melinda Gates Foundation for the grant that allows us to build on our collaborative track record of bringing effective and life-saving vaccines to children and adults in communities with limited infrastructure,” said Steven Damon, CEO of Micron Biomedical. “By supporting Micron’s efforts to develop a state-of-the-art, high-quality and large-scale production facility to manufacture our microarray technology, we have an opportunity to greatly improve on access and availability of measles/rubella vaccines, as well as other traditionally-injectable

Global Health vaccines, in underserved populations around the world. This first commercial-scale production facility establishes Micron’s proof of concept for additional commercial vaccines and drugs in all markets globally.”

Micron’s technology has been recognized for its potential to achieve positive global impact. In addition to the opportunity to improve access to vaccines and therapeutics in low- and middle-income countries, Micron’s technology has an opportunity to improve health globally as the evidence reflects that patient reluctance to receive injectable medicine can lead to delayed therapy, treatment avoidance, and vaccine hesitancy in higher income countries. The technology’s broad impact also includes US national health security, as well as veteran and military health.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Kazia has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,444,445 ADSs. The warrants will have an exercise price of $0.583 per ADS, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about December 5, 2023, subject to the satisfaction of customary closing conditions.
The groundbreaking ColoSeal System™ enables minimally invasive colorectal tumor removal, eliminating the need for 2 open surgeries in today's standard of care notes Savage Medical.
Alto Neuroscience advises the funds will be used to support ongoing and planned late-stage clinical development of CNS product candidates with four Phase 2 readouts expected across the next 12-18 month
Ann Lin, co-founder and CEO of Cromatic said, "Outsourcing R&D is one of the most powerful ways for innovative biotech companies to get off the ground. While founders of tech giants like Apple and Google could build their products in garages with minimal resources, founders in biotech are confronted with the capital expense of lab space and equipment and the lengthy process of building the right team before they can even test their ideas. That’s why we are building the most powerful R&D outsourcing platform for biotechs, so that scientists will have clarity, confidence and choice when evaluating and managing their service providers. Ultimately, we want to enable biotech companies to start in garages, just like tech giants.”
The financing will support a substantial production capacity increase for the unique MIMIX™ hydrophilic biomaterial vascular access devices developed by AVI, which are designed to evade the foreign body reaction by mimicking the human body’s natural chemistry, as well as further research into the potential for MIMIX to lower catheter infection rates, and expansion of AVI’s product portfolio notes Access Vascular.

By using this website you agree to accept Medical Device News Magazine Privacy Policy